{"id":"mepivaca-ne","safety":{"commonSideEffects":[{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nervousness"},{"rate":null,"effect":"Allergic reactions (rare with amides)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mepivacaine reversibly inhibits sodium influx into nerve fibers by binding to sodium channels from the intracellular side, thereby stabilizing the neuronal membrane and raising the threshold for electrical excitability. This action prevents depolarization and propagation of action potentials, resulting in local anesthesia. The drug is an amide-type local anesthetic with intermediate duration of action.","oneSentence":"Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:32.461Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Local and regional anesthesia for dental procedures"},{"name":"Local and regional anesthesia for minor surgical procedures"},{"name":"Infiltration anesthesia"}]},"trialDetails":[{"nctId":"NCT05252117","phase":"PHASE4","title":"Uterovaginal Plexus Block With Articaine for Intrauterine Device Placement Patients Who Are Indicated for the Use of Copper IUD as a Contraceptive Method Will be Invited to Participate in This Research.","status":"UNKNOWN","sponsor":"Universidade do Vale do Sapucai","startDate":"2021-02-01","conditions":"Contraception, IUD, Anesthesia, Local","enrollment":240},{"nctId":"NCT02909049","phase":"PHASE4","title":"Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy","status":"COMPLETED","sponsor":"Complexo Hospitalario Universitario de A Coruña","startDate":"2016-04","conditions":"Prostatic Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1926,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MEPIVACAINE 2% ATC N01BB03 MAN 62606"],"phase":"marketed","status":"active","brandName":"MEPIVACAÍNE","genericName":"MEPIVACAÍNE","companyName":"Complexo Hospitalario Universitario de A Coruña","companyId":"complexo-hospitalario-universitario-de-a-coru-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mepivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of nerve impulses. Used for Local and regional anesthesia for dental procedures, Local and regional anesthesia for minor surgical procedures, Infiltration anesthesia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}